About the Product

Description


Darihype 15 Tablet containing Darifenacin is used for the management of overactive bladder symptoms. It helps in reducing urinary urgency, increased frequency, and urge incontinence.

Darifenacin works as an antimuscarinic agent that relaxes bladder muscles, helping improve bladder control and reduce unwanted urinary contractions.

The tablet is widely prescribed in urology practice for long-term bladder management, leading to consistent demand and repeat usage.

With increasing prevalence of urinary disorders and growing awareness of urological health, this product offers strong business potential for retailers and distributors. Its chronic therapy requirement, steady prescription demand, and broad clinical acceptance make it a reliable product for consistent sales and growth in the urology segment.

Some patients may experience dry mouth, constipation, blurred vision, headache, or dizziness. Rarely, urinary retention or severe allergic reactions may occur and require medical attention.

Darihype 15 Tablet is indicated for the treatment of overactive bladder with symptoms such as urinary urgency, increased frequency of urination, and urge urinary incontinence. It helps improve bladder capacity, reduce urinary leakage, and enhance patient comfort.

This medicine should be used under medical supervision. Use cautiously in patients with glaucoma, urinary retention, gastrointestinal obstruction, or liver disorders. Adequate hydration and monitoring are advised during therapy.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Darihype 15 Tablet in the PCD pharma franchise market?

Darihype 15 Tablet, containing Darifenacin 15mg, has strong demand in the urology segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on urinary disorders and specialty urology portfolios.

Why should medical distributors include Darihype 15 Tablet in their product range?

Medical distributors and agencies can benefit from the consistent demand for antimuscarinic agents used in overactive bladder (OAB), urinary urgency, frequency, and incontinence management. Darihype 15 Tablet helps strengthen a comprehensive urology product portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for Darihype 15 Tablet?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Darihype 15 Tablet with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for Darihype 15 Tablet distribution?

Wholesalers and medical agencies benefit from steady urology prescription demand, reliable availability, good margins, and professional support when partnering for Darihype 15 Tablet distribution.

How can I become a distributor or franchise partner for Darihype 15 Tablet?

Medical distributors, stockists, and wholesalers interested in Darihype 15 Tablet can contact Cafoli LifeCare Pvt Ltd to discuss franchise opportunities, bulk supply requirements, pricing, and distribution support.